Shots:

• The study involves assessing of Praluent (75mg & 150mg- q2w) vs PBO in patients with MACE events and experienced ACS between 1 to 12 mos. in 18-924 patients for duration of 2.8 years
• The results included 29% reduction in rates of mortality with LDL-C level 100 mg/dL& reduction in cardiovascular events- with no new safety signals observed
• Praluent IV inhibitor of PCSK9- jointly developed by Regeneron & Sanofi- using Regeneron’s VelocImmune technology. The above data is submitted under EU & has received a PDUFA date as 28 Apr- 2018 from FDA

Ref: Regeneron | Image: Bam Studio